Research programme: diabetic complications and autoimmune disorder therapeutics - Dynamis Pharmaceuticals

Drug Profile

Research programme: diabetic complications and autoimmune disorder therapeutics - Dynamis Pharmaceuticals

Alternative Names: DYN 12; DYN 15

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Dynamis Therapeutics
  • Developer Dynamis Pharmaceuticals
  • Class Organic chemicals; Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic complications
  • Research Autoimmune disorders

Most Recent Events

  • 02 Mar 2017 Preclinical development is ongoing for Diabetic complications in USA (Dynamis Pharmaceuticals Presentation)
  • 02 Mar 2017 Early research in Autoimmune disorders in USA (PO) (Dynamis Pharmaceuticals Presentation) before March 2017
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-complications in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top